Soluble CD164 polypeptides
View Patent ↗The present invention relates to sCD164 variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders.
1. An isolated sCD164 variant polypeptide selected from:
(i) a polypeptide comprising SEQ ID NO: 16;
(ii) a fusion protein comprising SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer; or
(iii) a polypeptide comprising SEQ ID NO: 16 and a signal sequence.
2. The isolated sCD164 variant polypeptide according to claim 1 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16.
3. The isolated sCD164 variant polypeptide according to claim 1 , wherein said sCD 164 variant polypeptide comprises SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer.
4. The isolated sCD164 variant polypeptide according to claim 1 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16 and a signal sequence.
5. A composition comprising a pharmaceutically acceptable carrier and a sCD 164 variant polypeptide selected from:
(i) a polypeptide comprising SEQ ID NO: 16;
(ii) a fusion protein comprising SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer; or
(iii) a polypeptide comprising SEQ ID NO: 16 and a signal sequence.
6. The composition according to claim 5 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16.
7. The composition according to claim 5 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer.
8. The composition according to claim 5 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16 and a signal sequence.